Simponi, Enbrel set to fuel competition in rheumatism drug market

New brand Simponi (golimumab) and Enbrel (etanercept 50 mg) prefilled syringe are expected to rev up the domestic rheumatism drug market, which is valued at 85 billion won.

So far, three products, such as Janssen’s Remicade (infliximab), Abbott's Humira (adalimumab) and Pfizer’s Enbrel have been spotlighted as leading market runners with a bigger share.

For now, industry watchers say, the...